Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS-9821 inhalation suspension in moderate to severe chronic obstructive pulmonary disease
CTR20262233Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9821 in chronic obstructive pulmonary disease (COPD), sponsored by Hengrui Therapeutics. Started Jul 2026; status: active.
02
Drugs
HRS-9821
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20262233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262233.